Down Syndrome
Screening & Diagnostic Pathway for Down Syndrome Under 7
Down syndrome is confirmed by karyotype after antenatal or birth detection; in the under-7 child the pathway centres on scheduled comorbidity screening (cardiac, audiology, thyroid, ophthalmology) and continuous structured developmental surveillance to start early intervention promptly.
A child with Down syndrome rarely needs a label confirmed before support begins — but a clear, staged pathway turns suspicion into timely, coordinated care.
In short
Down syndrome (ICD-11 LD40.0) is most often suspected antenatally (combined first-trimester screening, NIPT) or at birth on recognisable phenotype, and confirmed by karyotype/chromosomal microarray. In the under-7 child the clinician's task is no longer diagnostic confirmation but structured developmental surveillance and proactive comorbidity screening, so that early-intervention therapy starts without delay.The pathway, briefly
Confirm and characterise. Where the diagnosis is clinical, send karyotype to define trisomy 21, translocation or mosaicism (translocation prompts parental karyotyping for recurrence counselling).Screen the known comorbidities — on schedule. Following AAP/IAP health-supervision guidance: echocardiography in the neonatal period (≈50% have congenital heart disease); newborn and serial audiology; ophthalmology review; thyroid function at birth then periodically; haematology for transient myeloproliferative disorder; feeding, growth on Down-specific charts; cervical-spine symptom vigilance; coeliac and obstructive sleep apnoea surveillance as the child grows.
Surveil development continuously. Use a structured developmental measure at every health-supervision visit rather than a one-off screen — expressive language, fine and gross motor, and social-adaptive domains warrant the closest tracking, and a clinician-administered profile gives a reliable baseline to plan against.
The Pinnacle way
A clinical AbilityScore® and any diagnosis are formed only at a Pinnacle Blooms Network centre, under qualified clinician care — never from an app or this page. We translate the medical diagnosis into a measurable developmental baseline and a coordinated plan spanning speech therapy and occupational therapy, tracked over time via the AbilityScore®. See the Down syndrome pathway for the full developmental picture.Trusted sources
WHO ICD-11 (LD40.0); AAP health-supervision guidance for children with Down syndrome via HealthyChildren.org; CDC developmental milestones; Indian Academy of Pediatrics.Next step — Refer the child for a structured AbilityScore® baseline and an early-intervention plan at a Pinnacle Blooms Network centre.
This is general information, not a diagnosis — a clinical AbilityScore® and any diagnosis are formed only at a Pinnacle Blooms Network centre under qualified clinician care.
What to watch
Track expressive language, fine and gross motor milestones and social-adaptive skills at every visit; stay alert to cardiac, hearing, thyroid, vision, coeliac, sleep-apnoea and cervical-spine signs on the AAP/IAP schedule.
Try this at home
Use Down syndrome-specific growth charts rather than standard ones, and document each comorbidity screen against its recommended age so nothing is missed across the early years.
Trusted sources
Developed by SETU Consortium · Pinnacle Blooms Network · Last reviewed 2026-06-10
This is general information, not a diagnosis. A clinical AbilityScore® and any diagnosis are formed only at a Pinnacle Blooms Network centre, under qualified clinician care.
Frequently asked
Is karyotype still needed if the diagnosis is clinically obvious at birth?
Yes. Karyotype (or chromosomal microarray) confirms the diagnosis and defines whether it is trisomy 21, translocation or mosaicism. Translocation findings prompt parental karyotyping for recurrence-risk counselling.
Which comorbidity screens are most time-critical in infancy?
Neonatal echocardiography for congenital heart disease, newborn and serial audiology, thyroid function, ophthalmology review and haematology for transient myeloproliferative disorder are the early priorities, following AAP/IAP health-supervision schedules.
When should developmental assessment begin?
From birth and continuously. Use a structured developmental measure at every health-supervision visit so early intervention starts without waiting for any single milestone to be missed.